Elucidating the role of muscarinic receptors in psychosis

Life Sciences

Volumn 68, Issue 22-23, 2001, Pages 2605-2613

  Felder, Christian C ^a   Porter, Amy C ^a   Skillman, Tiffanie L ^a   Zhang, Lu ^a   Bymaster, Frank P ^a   Nathanson, Neil M ^b   Hamilton, Susan E ^b   Gomeza, Jesus ^c   Wess, Jurgen ^c   McKinzie, David L ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cognition; GTP binding; Muscarinic receptor subtypes; Psychosis; Schizophrenia; Startle reflex

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PROTEIN SUBUNIT;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION; BRAIN CORTEX; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPUS; LOCOMOTION; MOUSE; NONHUMAN; PREPULSE INHIBITION; PSYCHOSIS; RECEPTOR BINDING; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STARTLE REFLEX;

EID: 0035957552     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(01)01059-1     Document Type: Conference Paper

References (19)

1. Abood LG Biel JH. Anticholinergic psychotomimetic agents. International Review of Neurobiology 1962; 4: 217-273.
2. Baumgold J, Abood LG Aronstam R. Studies on the relationship of binding affinity to psychoactive and anticholingergic potency of a group of psychotomimetic glycolates. Brain Research 1977; 124: 331-40.
3. Granacher RP Baldessarini RJ. Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Archives of General Psychiatry 1975; 32: 375-80.
4. Fisher CM. Visual hallucinations on eye closure associated with atropine toxicity. A neurological analysis and comparison with other visual hallucinations. Canadian Journal of Neurological Sciences 1991; 18: 18-27.
5. Fisher A, Brandeis R, Haring R, Eshhar N, Heldman E, Karton Y, Eisenberg O, Meshulam H, Marciano D, Bar-Ner N Pittel Z. Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis. [Review] [20 refs]. Journal of Physiology, Paris 1998; 92: 337-40.
6. Bymaster FP, Shannon HE, Rasmussen K, Delapp NW, Mitch CH, Ward JS, Calligaro DO, Ludvigsen TS, Sheardown MJ, Olesen PH, Swedberg MD, Sauerberg P Fink-Jensen A. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane. European Journal of Pharmacology 1998; 356: 109-19.
7. Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R Paul SM. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Disease & Associated Disorders 1997; 11 Suppl 4: S16-22.
8. Shannon HE, Hart JC, Bymaster FP, Calligaro DO, Delapp NW, Mitch CH, Ward JS, Fink-Jensen A, Sauerberg P, Jeppesen L, Sheardown MJ Swedberg MDB. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. Journal of Pharmacology and Experimental Therapeutics 1999; 290: 901-907.
9. DeLapp NW, McKinzie JH, Sawyer BD, Vandergriff A, Falcone J, McClure D Felder CC. Determination of [35S]guanosine-5′-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. Journal of Pharmacology & Experimental Therapeutics 1999; 289: 946-55.
10. Hamilton SE, Loose MD, Qi M, Levey AI, Hille B, McKnight GS, Idzerda RL Nathanson NM. Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proceedings of the National Academy of Sciences of the United States of America 1997; 94: 13311-6.
11. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, Shannon H, Xia B, Deng C Wess J. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 10483-8.
12. Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Brodkin J, Grinberg A, Sheng H Wess J. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 1692-7.
13. Ethier MF, Schaefer OP, Samant N, Yamaguchi H Madison JM. Muscarinic receptor reserve for inhibition of cAMP accumulation in bovine trachealis cells. American Journal of Physiology 1996; 270: L199-207.
14. Felder CC, Poulter MO Wess J. Muscarinic receptor-operated Ca2+ influx in transfected fibroblast cells is independent of inositol phosphates and release of intracellular Ca2+. Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 509-13.
15. Brann MR, Buckley NJ, Jones SV Bonner TI. Expression of a cloned muscarinic receptor in A9 L cells. Molecular Pharmacology 1987; 32: 450-5.
16. Jentsch JD Roth RH. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20: 201-25.
17. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Experimental Neurology 2000; 163: 495-529.
18. Felder CC. Muscarinic acetylcholine receptors: Signal transduction through multiple effectors. [Review] [97 refs]. FASEB Journal 1995; 9: 619-25.
19. Levey AI, Kitt CA, Simonds WF, Price DL Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. Journal of Neuroscience 1991; 11: 3218-26.